Dr. Ramin Ebrahimi MD
Director of Cardiac Catheterization Lab, Wadsworth VA Medical Center
Member of the Healthcare Council
Council Member Biography
Ramin Ebrahimi, MD, is Clinical Professor at UCLA. He is also Director of Interventional Cardiovascular Research and Co-Director of the Cardiac Catheterization Laboratory and Assistant Director of Nuclear Cardiology at the Wadsworth VA Medical Center. Dr. Ebrahimi's clinical and research interests focus on interventional cardiology, acute coronary syndromes (ACS), invasive and interventional devices, obesity, dyslipidemia, and peripheral arterial disease. He is Principal Investigator on various clinical trials and has made several contributions to ACS and interventional cardiology literature. Dr. Ebrahimi is a national speaker in the fields of ACS and peripheral arterial disease. He is on the editorial board of Therapy and the Journal of Cardiovascular Pharmacology and Therapeutics. Dr. Ebrahimi is a reviewer for many journals including the Journal of the Amreican College of Cardiology, Circulation, and American Journal of Cardiology. He is also an invited faculty to the TCT meetings. (This is me - Update Profile)
Employment History
- 1999 - Unspecified
- Clinical Professor , UNIVERSITY OF CALIFORNIA, LOS ANGELES
- 1999 - Unspecified
- Director of Cardiac Catheterization Lab, Wadsworth VA Medical Center
- 1995 - 1999
- Assistant Clinical Professor, University of California Irvine
- 1994 - 1995
- Instructor in Medicine, TRUSTEES OF BOSTON UNIVERSITY
GLG NewsSM Analyses by Ramin Ebrahimi
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
November 23, 2007
Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events | pharmalive.com
The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.
-
Good device but not much improvement.
August 31, 2007
St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
The repositioning of the hole, also present with the VIP version is a mild improvement to decrease sheath manipulation. Otherwise the device has not changed much in the past few years. While a very good device in general, its primary limitaions listed below still remain. 1. not allowing re-access at the previous access site within 90 days of the index procedure 2. inability to promote means for primary healing of the arteriotomy site (primary healing results in much less scar formation and secondary healing that angioseal provides) and 3. relying on an intravascular component for deployment that stays within the vessel for weeks prior to its resolution Newer devices such as the STARCLOSE that also are easy to deploy, rely on no intravascular components and potentially provide much better healing process may be the way of future.
GLG Study Groups with Ramin Ebrahimi(?)
GLG Live Meetings with Ramin Ebrahimi(?)
Ramin Ebrahimi has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.